Both SCFAs are known to affect the pathogenesis of Alzheimer’s disease through the inhibition of microglia- and astrocyte-induced inflammation, and aggregations of Aβ and Tau (Kumar et al., 2010; Macfarlane and Macfarlane, 2012). This evidence concerns the gene MAPT and Alzheimer disease.